<p>Geode Capital Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第四季度将其在 Celcuity, Inc.（NASDAQ:CELC - 免费报告）股票中的持仓提高了 8.4%。该公司在本季度额外收购了 64,213 股后，持有 830,684 股 Celcuity 的股票。到最近一个季度末，Geode Capital Management LLC 拥有约 1.80% 的 Celcuity，价值 82,872,000 美元。</p>
<ul>
<li>你会希望在 2026 年之前购买的 3 只股票</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对其在 CELC 的持仓进行了调整。EverSource Wealth Advisors LLC 在第四季度将其在 Celcuity 的股份增加了 1,329.2%。EverSource Wealth Advisors LLC 现在拥有 343 股该公司的股票，价值 34,000 美元，此前在此期间额外收购了 319 股。US Bancorp DE 在第三季度将其在 Celcuity 的股份增加了 25.4%。US Bancorp DE 现在拥有 706 股该公司的股票，价值 35,000 美元，此前在此期间额外收购了 143 股。BNP Paribas Financial Markets 在第二季度将其在 Celcuity 的股份增加了 78.9%。BNP Paribas Financial Markets 现在拥有 2,647 股该公司的股票，价值 35,000 美元，此前在此期间额外收购了 1,167 股。Ogorek Anthony Joseph NY ADV 在第四季度将其在 Celcuity 的股份增加了 19.7%。Ogorek Anthony Joseph NY ADV 现在拥有 662 股该公司的股票，价值 66,000 美元，此前在此期间额外收购了 109 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Celcuity 的股份增加了 211.2%。Tower Research Capital LLC TRC 现在拥有 5,549 股该公司的股票，价值 74,000 美元，此前在此期间额外收购了 3,766 股。机构投资者持有该公司 63.33% 的股票。</p>
<h2>Celcuity 关键新闻</h2>
<p>以下是本周影响 Celcuity 的关键新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 维持对 Celcuity 的 <strong>买入</strong> 评级，并设定 <strong>145 美元的目标价</strong>，其长期预测仍暗示到 2028-2030 年具有显著的盈利潜力。</li>
<li>中性情绪：该公司还宣布了一项 <strong>增大至 5 亿美元的可转换高级票据发行，截止日期为 2032 年</strong>，这改善了开发资金，但也引发了对股东稀释的担忧。Celcuity 宣布增大公共发行 0.250% 可转换高级票据的定价，截止日期为 2032 年。</li>
<li>中性情绪：Celcuity 将其 <strong>第三阶段 VIKTORIA-2</strong> 试验扩展至包括内分泌敏感型乳腺癌患者，如果研究继续顺利推进，这一发展可能会扩大市场机会。Celcuity 扩展第三阶段 VIKTORIA-2 试验以包括内分泌敏感型乳腺癌患者。</li>
<li>消极情绪：HC Wainwright <strong>下调了 Celcuity 的近期和中期每股收益预期</strong>，包括对 <strong>2026 财年、2027 财年、2028 财年、2029 财年和 2026 年第四季度</strong> 的低预期，表明对持续亏损的预期，直到最终盈利。</li>
<li>消极情绪：投资者情绪似乎也受到影响，因为有报道称 Celcuity 的股票在 <strong>试验结果让一些投资者失望后下跌</strong>，尽管其他报道将晚期乳腺癌数据描述为潜在强劲或 “改变实践”。ASCO26：Celcuity 因试验让投资者失望而受到惩罚。</li>
</ul>
<h2>内部活动</h2>
<p>在其他 Celcuity 新闻中，董事 David Dalvey 于 5 月 4 日星期一出售了 25,000 股公司的股票。该股票以平均价格 140.68 美元出售，总价值为 3,517,000.00 美元。出售后，该董事持有 65,000 股公司的股票，价值 9,144,200 美元。这笔交易代表其持仓减少了 27.78%。该交易已在向美国证券交易委员会的法律文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Richard E. Buller 于 5 月 4 日星期一出售了 9,000 股公司的股票。该股票以平均价格 140.46 美元出售，总价值为 1,264,140.00 美元。完成出售后，该董事直接持有 6,760 股公司的股票，价值约 949,509.60 美元。这笔交易代表其持仓减少了 57.11%。该出售的披露信息可在美国证券交易委员会的文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 5,111,950 美元的 37,000 股公司股票。内部人士持有公司 13.33% 的股票。</p>
<h2>分析师评级调整</h2>
<p>CELC 最近成为多份研究报告的主题。富国银行将 Celcuity 的目标价从 183.00 美元下调至 166.00 美元，并在周三的报告中对该股票设定了 “超配” 评级。Guggenheim 在周三的报告中重新发布了对 Celcuity 股票的 “买入” 评级。Wolfe Research 在 3 月 12 日的报告中重新发布了 “跑赢大盘” 评级，并设定了 110.00 美元的目标价。HC Wainwright 在 6 月 3 日的报告中将 Celcuity 的目标价从 185.00 美元下调至 145.00 美元，并对该股票设定了 “买入” 评级。最后，Citizens Jmp 在 5 月 4 日的报告中将 Celcuity 的目标价从 150.00 美元上调至 160.00 美元，并给予该股票 “市场跑赢大盘” 评级。十一位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，Celcuity 的平均评级为 “适度买入”，平均目标价为 152.09 美元。</p>
<p><strong>阅读我们关于 CELC 的最新报告</strong></p>
<h2>Celcuity 股票表现</h2>
<p>NASDAQ:CELC 周一开盘价为 88.28 美元。该公司的 50 日移动平均价格为 122.01 美元，200 日移动平均价格为 111.52 美元。Celcuity, Inc. 的 12 个月最低价为 11.27 美元，最高价为 151.02 美元。该股票的市值为 43.1 亿美元，市盈率为 -22.64，贝塔值为 0.10。公司快速比率为 12.31，流动比率为 12.31，债务与股本比率为 6.04。</p>
<p>Celcuity (NASDAQ:CELC - 获取免费报告) 最近一次发布季度财报是在 5 月 14 日星期四。公司报告该季度每股收益为 -0.97 美元，超出市场普遍预期的 -1.07 美元，超出幅度为 0.10 美元。整体来看，股票分析师预测 Celcuity, Inc. 本财年的每股收益将为 -3.69。</p>
<h2>关于 Celcuity</h2>
<p>(免费报告)</p>
<p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能性分析与分子分析相结合，Celcuity 力求优化治疗选择，提高实体肿瘤患者的治疗效果。</p>
<p>Celcuity 的专有平台通过使用外源性检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Celcuity 更好</li>
<li>这三只保险股创下 52 周新高：还有买入的机会吗？</li>
<li>三只股价低于 20 美元的股票，适合在更广泛的市场反弹前买入</li>
<li>Petco 面临激烈竞争，但势头正在增强</li>
<li>锁定效应是真实存在的——这三家建筑商正在押注于此</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
<p>在考虑 Celcuity 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，而 Celcuity 并不在名单上。</p>
<p>虽然 Celcuity 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

CELC

<p>Geode Capital Management LLC 在第四季度将其在 Celcuity, Inc. (NASDAQ:CELC) 的持股增加了 8.4%，增持了 64,213 股，总持股达到 830,684 股，价值约为 8290 万美元。其他机构投资者，包括 EverSource Wealth Advisors 和 Tower Research Capital 也扩大了他们的持仓。同时，内部人士 David Dalvey 和 Richard Buller 根据 10b5-1 计划出售了股份。分析师的情绪仍然不一，HC Wainwright 维持买入评级，尽管下调了每股收益预期，而富国银行则下调了其目标股价</p>

<p>Geode Capital Management LLC lifted its position in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 8.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 830,684 shares of the company's stock after acquiring an additional 64,213 shares during the quarter. Geode Capital Management LLC owned approximately 1.80% of Celcuity worth $82,872,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Geode Capital Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第四季度将其在 Celcuity, Inc.（NASDAQ:CELC - 免费报告）股票中的持仓提高了 8.4%。该公司在本季度额外收购了 64,213 股后，持有 830,684 股 Celcuity 的股票。到最近一个季度末，Geode Capital Management LLC 拥有约 1.80% 的 Celcuity，价值 82,872,000 美元。</p>
</div><ul>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>你会希望在 2026 年之前购买的 3 只股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in CELC. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company's stock worth $34,000 after acquiring an additional 319 shares during the period. US Bancorp DE grew its stake in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company's stock worth $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after acquiring an additional 1,167 shares during the period. Ogorek Anthony Joseph NY ADV grew its stake in shares of Celcuity by 19.7% during the 4th quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company's stock worth $66,000 after acquiring an additional 109 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock worth $74,000 after acquiring an additional 3,766 shares during the period. Institutional investors own 63.33% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对其在 CELC 的持仓进行了调整。EverSource Wealth Advisors LLC 在第四季度将其在 Celcuity 的股份增加了 1,329.2%。EverSource Wealth Advisors LLC 现在拥有 343 股该公司的股票，价值 34,000 美元，此前在此期间额外收购了 319 股。US Bancorp DE 在第三季度将其在 Celcuity 的股份增加了 25.4%。US Bancorp DE 现在拥有 706 股该公司的股票，价值 35,000 美元，此前在此期间额外收购了 143 股。BNP Paribas Financial Markets 在第二季度将其在 Celcuity 的股份增加了 78.9%。BNP Paribas Financial Markets 现在拥有 2,647 股该公司的股票，价值 35,000 美元，此前在此期间额外收购了 1,167 股。Ogorek Anthony Joseph NY ADV 在第四季度将其在 Celcuity 的股份增加了 19.7%。Ogorek Anthony Joseph NY ADV 现在拥有 662 股该公司的股票，价值 66,000 美元，此前在此期间额外收购了 109 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Celcuity 的股份增加了 211.2%。Tower Research Capital LLC TRC 现在拥有 5,549 股该公司的股票，价值 74,000 美元，此前在此期间额外收购了 3,766 股。机构投资者持有该公司 63.33% 的股票。</p>
</div><h2>Key Celcuity News</h2>
<div class="lb-trans"><h2>Celcuity 关键新闻</h2>
</div><p>Here are the key news stories impacting Celcuity this week:</p>
<div class="lb-trans"><p>以下是本周影响 Celcuity 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright maintained a <strong>Buy</strong> rating and a <strong>$145 price target</strong> on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.</li>
<li>Neutral Sentiment: The company also announced an <strong>upsized $500 million convertible senior notes offering due 2032</strong>, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032</li>
<li>Neutral Sentiment: Celcuity expanded its <strong>Phase 3 VIKTORIA-2</strong> trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients</li>
<li>Negative Sentiment: HC Wainwright <strong>cut near- and medium-term EPS estimates</strong> for Celcuity, including lower projections for <strong>FY2026, FY2027, FY2028, FY2029, and Q4 2026</strong>, signaling expectations for continued losses before eventual profitability.</li>
<li>Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after <strong>trial results disappointed some investors</strong>, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 维持对 Celcuity 的 <strong>买入</strong> 评级，并设定 <strong>145 美元的目标价</strong>，其长期预测仍暗示到 2028-2030 年具有显著的盈利潜力。</li>
<li>中性情绪：该公司还宣布了一项 <strong>增大至 5 亿美元的可转换高级票据发行，截止日期为 2032 年</strong>，这改善了开发资金，但也引发了对股东稀释的担忧。Celcuity 宣布增大公共发行 0.250% 可转换高级票据的定价，截止日期为 2032 年。</li>
<li>中性情绪：Celcuity 将其 <strong>第三阶段 VIKTORIA-2</strong> 试验扩展至包括内分泌敏感型乳腺癌患者，如果研究继续顺利推进，这一发展可能会扩大市场机会。Celcuity 扩展第三阶段 VIKTORIA-2 试验以包括内分泌敏感型乳腺癌患者。</li>
<li>消极情绪：HC Wainwright <strong>下调了 Celcuity 的近期和中期每股收益预期</strong>，包括对 <strong>2026 财年、2027 财年、2028 财年、2029 财年和 2026 年第四季度</strong> 的低预期，表明对持续亏损的预期，直到最终盈利。</li>
<li>消极情绪：投资者情绪似乎也受到影响，因为有报道称 Celcuity 的股票在 <strong>试验结果让一些投资者失望后下跌</strong>，尽管其他报道将晚期乳腺癌数据描述为潜在强劲或 “改变实践”。ASCO26：Celcuity 因试验让投资者失望而受到惩罚。</li>
</ul>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Celcuity news, Director David Dalvey sold 25,000 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company's stock, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 37,000 shares of company stock worth $5,111,950. Insiders own 13.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Celcuity 新闻中，董事 David Dalvey 于 5 月 4 日星期一出售了 25,000 股公司的股票。该股票以平均价格 140.68 美元出售，总价值为 3,517,000.00 美元。出售后，该董事持有 65,000 股公司的股票，价值 9,144,200 美元。这笔交易代表其持仓减少了 27.78%。该交易已在向美国证券交易委员会的法律文件中披露，文件可在此链接查看。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Richard E. Buller 于 5 月 4 日星期一出售了 9,000 股公司的股票。该股票以平均价格 140.46 美元出售，总价值为 1,264,140.00 美元。完成出售后，该董事直接持有 6,760 股公司的股票，价值约 949,509.60 美元。这笔交易代表其持仓减少了 57.11%。该出售的披露信息可在美国证券交易委员会的文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 5,111,950 美元的 37,000 股公司股票。内部人士持有公司 13.33% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>CELC has been the topic of a number of recent research reports. Wells Fargo &amp; Company dropped their price objective on Celcuity from $183.00 to $166.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday. Guggenheim reissued a &#34;buy&#34; rating on shares of Celcuity in a report on Wednesday. Wolfe Research reissued an &#34;outperform&#34; rating and set a $110.00 price objective on shares of Celcuity in a report on Thursday, March 12th. HC Wainwright dropped their price objective on Celcuity from $185.00 to $145.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, June 3rd. Finally, Citizens Jmp increased their price objective on Celcuity from $150.00 to $160.00 and gave the stock a &#34;market outperform&#34; rating in a report on Monday, May 4th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Celcuity has an average rating of &#34;Moderate Buy&#34; and an average price target of $152.09.</p>
<div class="lb-trans"><p>CELC 最近成为多份研究报告的主题。富国银行将 Celcuity 的目标价从 183.00 美元下调至 166.00 美元，并在周三的报告中对该股票设定了 “超配” 评级。Guggenheim 在周三的报告中重新发布了对 Celcuity 股票的 “买入” 评级。Wolfe Research 在 3 月 12 日的报告中重新发布了 “跑赢大盘” 评级，并设定了 110.00 美元的目标价。HC Wainwright 在 6 月 3 日的报告中将 Celcuity 的目标价从 185.00 美元下调至 145.00 美元，并对该股票设定了 “买入” 评级。最后，Citizens Jmp 在 5 月 4 日的报告中将 Celcuity 的目标价从 150.00 美元上调至 160.00 美元，并给予该股票 “市场跑赢大盘” 评级。十一位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat，Celcuity 的平均评级为 “适度买入”，平均目标价为 152.09 美元。</p>
</div><p><strong>Read Our Latest Report on CELC</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CELC 的最新报告</strong></p>
</div><h2>Celcuity Stock Performance</h2>
<div class="lb-trans"><h2>Celcuity 股票表现</h2>
</div><p>NASDAQ:CELC opened at $88.28 on Monday. The business's 50-day moving average price is $122.01 and its two-hundred day moving average price is $111.52. Celcuity, Inc. has a twelve month low of $11.27 and a twelve month high of $151.02. The stock has a market cap of $4.31 billion, a P/E ratio of -22.64 and a beta of 0.10. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.</p>
<div class="lb-trans"><p>NASDAQ:CELC 周一开盘价为 88.28 美元。该公司的 50 日移动平均价格为 122.01 美元，200 日移动平均价格为 111.52 美元。Celcuity, Inc. 的 12 个月最低价为 11.27 美元，最高价为 151.02 美元。该股票的市值为 43.1 亿美元，市盈率为 -22.64，贝塔值为 0.10。公司快速比率为 12.31，流动比率为 12.31，债务与股本比率为 6.04。</p>
</div><p>Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, equities analysts predict that Celcuity, Inc. will post -3.69 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Celcuity (NASDAQ:CELC - 获取免费报告) 最近一次发布季度财报是在 5 月 14 日星期四。公司报告该季度每股收益为 -0.97 美元，超出市场普遍预期的 -1.07 美元，超出幅度为 0.10 美元。整体来看，股票分析师预测 Celcuity, Inc. 本财年的每股收益将为 -3.69。</p>
</div><h2>About Celcuity</h2>
<div class="lb-trans"><h2>关于 Celcuity</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.</p>
<div class="lb-trans"><p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能性分析与分子分析相结合，Celcuity 力求优化治疗选择，提高实体肿瘤患者的治疗效果。</p>
</div><p>Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.</p>
<div class="lb-trans"><p>Celcuity 的专有平台通过使用外源性检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?</li>
<li>3 Stocks Under $20 to Buy Before a Broader Market Rally</li>
<li>Petco Faces Tough Competition, But Momentum Is Building</li>
<li>The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Celcuity 更好</li>
<li>这三只保险股创下 52 周新高：还有买入的机会吗？</li>
<li>三只股价低于 20 美元的股票，适合在更广泛的市场反弹前买入</li>
<li>Petco 面临激烈竞争，但势头正在增强</li>
<li>锁定效应是真实存在的——这三家建筑商正在押注于此</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Celcuity 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在买入的股票，而 Celcuity 并不在名单上。</p>
</div><p>While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celcuity 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC

Market Beat

Celcuity

美国合众银行

法国巴黎银行(ADR)

富国银行

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Geode Capital Management LLC 购买了 Celcuity, Inc.的 64,213 股股票 $CELC